Skip to content

The Ring Study, a phase 3 trial, showed a favourable safety profile and a 31% HIV infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article outlines the DREAM study, which aimed to evaluate safety, adherence, and HIV incidence in those using the dapivirine vaginal ring (DVR) in open-label use.

Featured Resources